These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26809629)

  • 1. Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B.
    Jun BG; Lee SH; Kim HS; Kim SG; Kim YS; Kim BS; Jeong SW; Jang JY; Kim YD; Cheon GJ
    Korean J Gastroenterol; 2016 Jan; 67(1):28-34. PubMed ID: 26809629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B.
    Song MJ; Song DS; Kim HY; Yoo SH; Bae SH; Choi JY; Yoon SK; Paik YH; Lee JS; Lee HW; Kim HJ
    World J Gastroenterol; 2012 Nov; 18(43):6277-83. PubMed ID: 23180949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on Post-Treatment Relapse in HBeAg Positive CHB Patients.
    Lu J; Li J; Liu Y; Ren S; Cao Z; Jin Y; Ma L; Shen C; Chen X
    PLoS One; 2015; 10(11):e0141072. PubMed ID: 26524467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Virologic response to adefovir dipivoxil monotherapy is not durable in HBeAg-positive, lamivudine-resistant chronic hepatitis B patients].
    Jung HW; Choi MS; Kim KH; Park SH; Yeon KK; Lee JH; Koh KC; Paik SW; Yoo BC
    Korean J Hepatol; 2009 Mar; 15(1):52-8. PubMed ID: 19346785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir.
    Ridruejo E; Marciano S; Galdame O; Reggiardo MV; Muñoz AE; Adrover R; Cocozzella D; Fernandez N; Estepo C; Mendizábal M; Romero GA; Levi D; Schroder T; Paz S; Fainboim H; Mandó OG; Gadano AC; Silva MO
    J Viral Hepat; 2014 Aug; 21(8):590-6. PubMed ID: 24188363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status.
    Liu F; Liu ZR; Li T; Liu Y; Zhang M; Xue Y; Zhang LX; Ye Q; Fan XP; Wang L
    J Dig Dis; 2018 Sep; 19(9):561-571. PubMed ID: 30098114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
    Chen CH; Hung CH; Hu TH; Wang JH; Lu SN; Su PF; Lee CM
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation.
    Kim JH; Lee SJ; Joo MK; Kim CH; Choi JH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    Dig Dis Sci; 2009 Jul; 54(7):1572-7. PubMed ID: 18975080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
    He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
    Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients.
    Kim YJ; Kim K; Hwang SH; Kim SS; Lee D; Cheong JY; Cho SW
    Clin Mol Hepatol; 2013 Sep; 19(3):300-4. PubMed ID: 24133668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study.
    Kang SH; Kang K; Jong Eun Y; Lee YS; Kim TS; Yoo YJ; Suh SJ; Yoon EL; Jung YK; Kim JH; Seo YS; Yim HJ; Byun KS
    J Med Virol; 2017 May; 89(5):849-856. PubMed ID: 27769101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir discontinuation after long-term viral suppression in HBeAg negative chronic hepatitis B. Can HBsAg levels be useful?
    Buti M; Casillas R; Riveiro-Barciela M; Homs M; Tabernero D; Salcedo MT; Rodriguez-Frias F; Esteban R
    J Clin Virol; 2015 Jul; 68():61-8. PubMed ID: 26071338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases].
    Jeong Id; Park NH; Kim BC; Park JH; Seo KW; Kim DH; Joo KR; Kim DH
    Taehan Kan Hakhoe Chi; 2003 Jun; 9(2):69-78. PubMed ID: 12824746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy.
    Liang Y; Jiang J; Su M; Liu Z; Guo W; Huang X; Xie R; Ge S; Hu J; Jiang Z; Zhu M; Wong VW; Chan HL
    Aliment Pharmacol Ther; 2011 Aug; 34(3):344-52. PubMed ID: 21671967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
    Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
    Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.